Nauman Shah

Vice President, Enterprise Program Office Management at Johnson & Johnson


Nauman is the Vice President of Enterprise Program Office Management at Johnson & Johnson.  In this role, he successfully led the launch of INVOKANA.   Nauman is a member of the Leadership Team for Cardiovascular and Metabolism, in addition to many other internal partnership teams.  Nauman has a strong track record of business results and proven leadership skills.

Prior to joining the Metabolics Team at J&J, Nauman held positions of increasing responsibility within the Cardiovascular Team, leading the launches of multiple indications for XARELTO®, the first Factor Xa Inhibitor launched in the United States.  In other roles, Nauman led Portfolio Strategy Efforts for the Johnson & Johnson Pharmaceutical Sector, and was responsible for the Strategy for the Early to Mid-Stage pipeline for Central Nervous Disorders.  He also led the launch of Topamax for Migraine Prevention in his first role at J&J.   Prior to joining Johnson & Johnson, Nauman worked at Pfizer/Pharmacia, where he played a major role in the successful launches of three major products in areas of Urology, Arthritis, and Pain.

Nauman holds a BA in Biological Basis of Behavior from the University of Pennsylvania, as well as an MBA in Finance from Temple University.